Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel  by Kawaishi, Makoto et al.
ORIGINAL ARTICLE
Circulating Endothelial Cells in Non-small Cell Lung Cancer
Patients Treated with Carboplatin and Paclitaxel
Makoto Kawaishi, MD,* Yutaka Fujiwara, MD,† Tomoya Fukui, MD,* Terufumi Kato, MD,*
Kazuhiko Yamada, MD,† Yuichiro Ohe, MD, PhD,† Hideo Kunitoh, MD, PhD,†
Ikuo Sekine, MD, PhD,† Noboru Yamamoto, MD, PhD,† Hiroshi Nokihara, MD, PhD,†
Takeshi Watabe, PhD,‡ Yuji Shimoda, PhD,‡ Tokuzo Arao, MD, PhD,§ Kazuto Nishio, MD, PhD,§
Tomohide Tamura, MD† and Fumiaki Koizumi, MD, PhD*
Introduction: Circulating endothelial cells (CECs) increase in can-
cer patients and play an important role in tumor neovascularization.
Methods: This study was designed to investigate the role of CEC as
a marker for predicting the effectiveness of a carboplatin plus
paclitaxel based first line chemotherapy in advanced non-small cell
lung cancer (NSCLC).
Results: The CEC count in 4 ml of peripheral blood before starting
chemotherapy (baseline value) was significantly higher in NSCLC
patients, ranging from 32 to 4501/4 ml (n  31, mean  SD 
595  832), than in healthy volunteers (n  53, 46.2  86.3). We
did not detect a significant correlation between the CEC count and
estimated tumor volume. CECs were significantly decreased by
chemotherapy as compared with pretreatment values (175.6  24
and 173.0  24, day 8, 22, respectively). We investigated the
correlation between baseline CEC and the clinical effectiveness of
chemotherapy. CEC values are significantly higher in patients with
clinical benefit (partial response and stable disease, 516  458,
870.8  1215, respectively) than in progressive disease patients
(211  150). Furthermore, a statistically significant decrease in
CECs, on day 22, was observed only in patients with partial
response. Patients who had a baseline CEC count greater than 400/4
ml showed a longer progression-free survival (400, 271 days
range: 181–361 versus 400, 34 range: 81–186, p  0.019).
Conclusion: CEC is suggested to be a promising predictive marker
of the clinical efficacy of the CBDCA plus paclitaxel regimen in
patients with NSCLC.
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Angiogenesis plays a critical role in the growth and me-tastasis of solid tumors.1 The clinical importance of
angiogenesis in human tumors has been demonstrated by
several reports indicating a positive relationship between the
blood vessel density in the tumor mass and poor prognosis,
i.e., survival, in patients with various types of cancers includ-
ing non-small cell lung cancer (NSCLC).2–6 Furthermore,
Natsume et al.7 reported the antitumor activities of anticancer
agents to be less active against vascular endothelial growth
factor-secreting cells (SBC-3/VEGF), in vivo as compared
with its mock transfectant (SBC-3/Neo). In recent years,
antiangiogenic agents have also been demonstrated to be
active against a variety of malignancies, including lung,
colorectal, and renal cancer.8–10 Thus, angiogenesis is a
promising target for cancer treatment and is related to the
prognosis and efficacy of these drugs, though the tumor
vessel biomarkers which predict the effectiveness of antian-
giogenic agents and other anticancer agents are not always
useful and have not become well-established.
Circulating endothelial cells (CECs) have been recog-
nized as a useful biomarker for vascular damage. CECs are
increased in cardiovascular disease, vasculitis, infectious dis-
ease, and various cancers.11–14 Recently, CECs were found to
be more numerous and viable in cancer patients than in
healthy subjects.14,15 Furthermore, elevated CECs in cancer
patients were found to be nearly normalized when the tumor
was removed surgically or with chemotherapy.15 Therefore,
most CECs are considered to be disseminated tissue endo-
thelial cells in the tumors and the CEC number may reflect
the extent of tumor angiogenesis. Indeed, the CEC level has
been demonstrated to correlate with the plasma level of
VEGF, one of the pivotal factors promoting tumor angiogen-
esis.15 Mancuso et al. reported that CEC kinetics and viability
are promising predictors of the response to chemotherapy
with antiangiogenic activity in patients with advanced breast
cancer.16 Thus, CEC is likely to be a useful marker for
predicting the effectiveness of chemotherapy as a noninva-
sive angiogenesis marker.
NSCLC is the leading cause of cancer-related death
worldwide. NSCLC accounts for approximately 50% of pa-
tients presenting with unresectable advanced stage,17 and
platinum-based chemotherapy offers only a small improve-
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ment in survival with advanced NSCLC.18,19 Over the past
decade, several new agents against NSCLC have become
available, including the taxanes, gemcitabine, vinorelbine,
and irinotecan. The combination of platinum and these new
agents has resulted in a high response rate and prolonged
survival compared with older chemotherapy regimens (e.g.,
vindesine, mitomycin, ifosfamide, with cisplatin). Therefore,
these regimens are considered standard chemotherapy for
advanced NSCLC.20–26 Although new agents have different
mechanisms of action, these combination regimens have not
been administered based on the biologic characteristics of
each tumor.
Paclitaxel inhibits several endothelial cell functions in
vitro such as proliferation, migration, morphogenesis, and
metalloprotease production.27–29 These activities result in
antiangiogenic activity in in vivo xenograft models.27,30 In-
terestingly, human endothelial cells are more sensitive to
paclitaxel than other cellular types.29 We hypothesized that
the CEC value is associated with tumor neovascularization,
which is one of the targets of paclitaxel. In the present study,
we investigated whether the CEC count at baseline is asso-
ciated with the effectiveness of the CDDP plus paclitaxel
regimen in patients with advanced-stage NSCLC.
MATERIALS AND METHODS
Patients
Patients with histologically or cytologically docu-
mented advanced NSCLC were eligible for this study. Each
patient was required to meet the following criteria: (1) no
prior treatment including chemotherapy, surgery, irradiation,
or any fluid drainage; (2) no prior general anesthesia for
diagnostic procedures including mediastinoscopy or thora-
coscopy; (3) no concomitant diseases including ischemic
heart diseases, systemic vasculitis, pulmonary hypertension,
or serious complications including infectious disease or dia-
betes; (4) written informed consent. The trial document was
approved by the institutional review board. The clinical
characteristics of the patients are shown in Table 1.
Treatment Schedule and Response Evaluation
All patients were treated according to the following
chemotherapeutic regimen: paclitaxel at 200 mg/m2 over a
3-hour period followed by carboplatin at a dose with an area
under the curve of 6 on day 1, repeated every 3 weeks. The
treatment was repeated for three or more cycles unless the
patients met the criteria for progressive disease (PD) or
experienced unacceptable toxicity.
The major axis (a) and minor axis (b) of the tumor mass
in each patient were measured with computed tomography.
Estimated tumor volume (ETV) was calculated using the
following formula; ETV  4/3   (a/2  b/2)  (a/2 
b/2)/2. Computed tomography examinations were performed
before treatment and with every one or two cycles of chemo-
therapy. Response was evaluated according to the RECIST,
and tumor markers were excluded from the criteria.31
Assay for CEC
Blood samples from NSCLC patients and healthy vol-
unteers were drawn into a 10-ml Cellsave Preservative Tube
(Immunicon Corp. Huntingdon Valley, PA) for CEC enumer-
ation. The CEC protocol used was approved by the Institu-
tional Review Board and written informed consent was ob-
tained from each subject. Samples from NSCLC were
obtained before (baseline) and 8 and 22 days after starting
chemotherapy. Samples were kept at room temperature and
processed within 42 hours after collection. All evaluations
were performed without knowledge of the clinical status of
the patients. The CellTracks system (Immunicon Corp) which
consists of CellTracks AutoPrep system and the CellSpotter
Analyzer system was used for endothelial cell enumera-
tion.32,33 In this system, CD146/DAPI/CD105-PE/
CD45APC- cells are defined as CECs. Briefly, cells which
express CD146 were immunomagnetically captured using
ferrofluids coated with CD146 antibodies. The enriched cells
were then labeled with the nuclear dye 4V,6-diamidino-2-
phenylindole (DAPI), CD105 antibodies conjugated to phy-
coerythrin (CD105-PE), and the pan-leukocyte antibody
CD45 conjugated to allophycocyanin (CD45-APC). In this
system, the CD146-enriched, fluorescently labeled cells were
identified as CECs when the cells exhibited the DAPI/
CD105/CD45- phenotype. We performed CEC enumera-
tion twice, using the same sample, and calculated the mean
value.
Statistical Analyses
This study was carried out as exploratory research for
detecting CECs from NSCLC patients. The number of en-
rolled patients was therefore not precalculated. Spearman’s
correlation analysis was performed to investigate the corre-
lation between CEC count and ETV. Between-group com-
parisons were made using the t test. The association between
CEC count and progression free survival (PFS) was estimated
using the Kaplan-Meier method. The log-rank test was used
to assess the survival difference between strata. Differences
were considered statistically significant at p  0.05.
TABLE 1. Baseline Characteristics of the Patients
Characteristic
N  31
No. (%)
Gender
Male 17 (55)
Female 14 (45)
Median age (yr) 60
Range 43–71
ECOG performance status
0 18 (58)
1 13 (42)
Stage
IIIA 2 (6)
IIIB 7 (23)
IV 22 (71)
Histology
Adenocarcinoma 23 (74)
Squamous cell carcinoma 4 (13)
Others 4 (13)
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RESULTS
Patient Characteristics
A total of 32 patients were enrolled in the study
between August 2005 and March 2006 (Table 1). One patient
withdrew consent to participate. Table 1 summarizes the
characteristics of the study population. The median age of the
patients was 60 years (range, 43–71). The histologic and/or
cytologic diagnosis was adenocarcinoma in 23 patients
(74.2%), squamous cell carcinoma in 4 (12.9%), and unclas-
sified NSCLC in 4 (12.9%). There were 17 males (54.8%).
The clinical stage was IIIA in 2 patients (6.5%), IIIB in 7
(22.6%), and IV in 22 (71.0%).
Ninety-two CEC samples from 31 patients (three sam-
ples per patient) were obtained and analyzed. One sample,
obtained 22 days after treatment, was not examined because
of inadequate collection.
Quantification of CEC
In 31 advanced NSCLC patients, CECs ranged from 32
to 4501 cells/4.0 ml of blood, mean  SD  595  832 at
baseline. CEC counts were elevated in a large portion of
patients with NSCLC as compared with healthy volunteers
(n  53, mean  SD  46.2  86.3/4 ml). Case 21 had an
exceptionally high CEC count (4501 at baseline). We did not
detect a significant correlation between the CEC count and
ETV in the 28 assessable patients (p  0.84, Figure 1). The
analysis of CECs during the first course of treatment showed
CEC levels to be reduced by CBDCA plus paclitaxel chemo-
therapy as compared with pretreatment values (176  141 at
8 days and 173  189 at 22 days after treatment) (Figure 2).
These reductions were significant (p  0.011 on day 8 and
p  0.04 on day 22), but there was no significant difference
between CEC amounts on day 8 versus day 22 (p  0.476).
There was no difference in the amount of CEC at baseline
when patients were subgrouped according to characteristics,
such as sex, smoking history, histologic type, and clinical
stage. Furthermore, there was no correlation of CEC amounts
with the blood examination data (e.g., number of white blood
cells, neutrophils, lymphocytes, hemoglobin, platelets, albu-
min, LDH, CRP, CEA, CYFRA).
CEC Amounts and Objective Tumor Response
to Chemotherapy
Thirteen (41.9%) of the 31 patients who received carbo-
platin and paclitaxel therapy showed a partial response (PR) and
12 (38.7%) showed stable disease (SD). The other 6 patients
(19.4%) showed PD. The amounts of CEC at baseline in the
patients who showed PR and SD were 516  458/4 ml and
871  1215/4 ml, respectively, and these values were signifi-
cantly higher than in PD patients (211  150/4 ml, p  0.023
and p  0.044, respectively) (Figure 3A). Although CEC dec-
rements during chemotherapy were observed in all three sub-
groups, the extent of the decrements tended to be greater in
0
500
1000
1500
0 50 100 150 200 250
Estimated tumor volume (cm3)
C
EC
 (b
as
el
in
e)
 / 
4 
m
l
FIGURE 1. Scatter plot analysis to determine the correla-
tion between the number of circulating endothelial cell
(CEC) and estimated tumor volume (ETV). ETV is calculated
with computed tomography (CT) examination. Case 21 is
not included.
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FIGURE 2. Circulating endothelial cell (CEC) levels during
the first course of CDDP plus paclitaxel chemotherapy. *p 
0.05 versus values at baseline.
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FIGURE 3. A, Comparison of circulating endothelial cell
(CEC) amount at baseline in non-small cell lung cancer
(NSCLC) patients with different clinical responses to CBDCA
plus paclitaxel chemotherapy. *p  0.05 versus values of
patients with progressive disease (PD). Case 21 is not in-
cluded. B, Relative change in CEC amount in patients with
partial response (PR), stable disease (SD), and PD.
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patients with PR and SD than in those with PD (Figure 3B). In
the subgroup analysis, a significant decrease in CECs was
observed on day 22 only in PR patients (p  0.018).
CEC Amounts and PFS
For all 31 patients, the median PFS was 154 days
(range, 81–361 days). Univariate analysis indicated that pa-
tients who had a CEC count of more than 400/4 ml at baseline
showed a significantly improved PFS (n  14, median; 244
days) (Log-rank test, p  0.019, Figure 4). A CEC count
below 400 at baseline was associated with a poorer PFS (n 
17, median; 69 days). The CEC count did not exceed the
value of 400/4 ml in any of the healthy volunteers. When we
compared the patients whose CEC counts exceeded 200 with
those whose counts were less than 200, a consistent differ-
ence in PFS was observed between the two groups (200;
n  22, median 227, 200; n  9, median 116, p  0.039).
DISCUSSION
In the present study, we investigated the number of CEC
during the first course of CBDCA plus paclitaxel chemotherapy.
To our knowledge, this is the first report of CEC in NSCLC
patients before treatment. Our findings demonstrated CEC
counts in advanced NSCLC at baseline level to be much higher
than those in healthy subjects (595 832/4.0 ml versus 32.6
29.5/4.0 ml). Because the NSCLC patients had not yet received
anticancer therapy, these increased CECs are likely to be mostly
derived from the tumor site. In a previous study, it was found
that the amounts of CECs correlate strongly with tumor volume
in vivo in an animal model34. Nevertheless, we did not find a
significant correlation between CECs and ETV. Because the
number of CECs could be influenced by many factors related to
tumor vasculature, neovascularization, and localization of the
tumor, our failure to identify a strong correlation in this study is
not surprising. We were also unable to detect a significant direct
correlation between CEC amounts and various blood examina-
tion data including tumor markers such as CEA and CYFRA. It
is unclear at present what biologic characteristics of the tumor or
clinical features the CEC number most closely reflects as a
biomarker. Mancuso et al. reported that CECs are strongly
associated with plasma levels of VCAM-1 and VEGF in breast
cancer and lymphoma patients.15,34 Because VCAM-1 and
VEGF are crucial factors for tumor angiogenesis, the variability
in CEC values among NSCLC patients might indicate a differ-
ence in the neovascularization of each tumor.
We were further able to demonstrate that elevated
CECs decreased dramatically after CBDCA plus paclitaxel
treatment, but did not reach the level of healthy subjects.
Decreased CEC values did not rise again during the first cycle
of chemotherapy. Although myelosupression was observed
on day 8 and recovered on day 22 in many patients (data not
shown), CEC kinetics do not parallel those of WBC, indicat-
ing that CEC kinetics might not be influenced by myelopoi-
esis. Several clinical studies in the field measuring CEC
found chemotherapy to be associated with either an increase
or a decrease in CECs.35–39 The different tumor types, stages,
prior therapy or not, the anticancer drugs used, measuring
points and quantification methods of CEC might have influ-
enced the CEC results after treatment. In the present study, the
pretreatment CEC value was much higher than that in lung
cancer with metastasis (mean  SD  146  270/4 ml), as
reported elsewhere.33 Although the details of the prior therapy in
patients with metastatic carcinoma were not provided,33 che-
motherapy can eventually decrease the CEC count.
Schiller et al. compared four standard chemotherapy
regimens, cisplatin plus paclitaxel, cisplatin plus gemcitab-
ine, cisplatin plus docetaxel, and carboplatin plus paclitaxel
and found no significant difference in survival.25 Despite the
different modes of action of each nonplatinum agent against
tumors and different biologic characteristics of each tumor,
we could not select the regimen based on these characteris-
tics. In our small study, the patients with PR/SD and longer
PFS had higher baseline CEC values. Therefore, it seems that
the baseline CEC count is a promising predictor of clinical
response to the CBDCA plus paclitaxel regimen and survival
in advanced NSCLC. If CEC is a marker for angiogenesis and
reflects tumor neovascularization, it is likely that a high CEC
is associated with a poor prognosis and lower effectiveness of
antiangiogenic therapy. Paclitaxel and docetaxel are catego-
rized as mitotic spindle agents with potent antiangiogenic
properties.27–30 This is why a paclitaxel based regimen might
be more effective against tumors with high CEC values.
Nevertheless, CEC counts have also been reported to be
increased in several clinical syndromes, such as cardiovascu-
lar diseases, infectious diseases, and vasculitides.11–13 The
CEC counts in patients with vasculitides have been reported
to be dozens of fold higher than those in healthy subjects,12
therefore, we have to consider the patient condition carefully
while interpreting the CEC counts in individual patients,
although there were no patients with vasculitis in the present
study. Further clinical investigation, with a similar approach,
including other nonplatinum anticancer agents, such as
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FIGURE 4. Progression-free-survival according to circulating
endothelial cell (CEC) count at baseline. The median dura-
tion of progression-free survival was greater in patients
whose CEC count exceeded 400 (median, 244 days) than in
patients whose CEC count was less than 400 (69 days).
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CDDP plus gemcitabine, is essential for the clinical applica-
tion of CEC for made-to-order chemotherapy in NSCLC.
Antiangiogenic therapy targeting the VEGF pathway
such as bevacizumab and VEGFR inhibitors have shown
promise in the treatment of solid tumors.8,39 These agents
inhibit endothelial cells through inhibition of the VEGF
pathway. It was recently demonstrated that the addition of
bevacizumab to CBDCA plus paclitaxel in advanced NSCLC
patients produces a significant survival benefit as compared
with chemotherapy alone.40 Considering the outstanding clin-
ical trial and our present study, it would be of great interest to
investigate the role of CEC in this regimen.
In conclusion, CECs were measured in NSCLC patients
before treatment. Our small clinical study indicates that the
CEC count at baseline is a potential biomarker for predicting
the response to chemotherapy and PFS, but further clinical
evaluation is needed. In the near future, we will start a clinical
investigation, using a similar approach, to examine other
chemotherapeutic regimens.
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